Brett Monia, CEO, Ionis Pharmaceuticals : It is. It's a growth market. It's clear that the size of this market continues to grow with new entrants coming into the market. It's been estimated to be $20, $30, $40 billion and growing. We believe that Waynua, eplontersen, will be a treatment of choice and do very well in this market once we get there for cardiomyopathy. There are two classes of mechanisms. There's a silencer class, like eplontersen, and then there's the stabilizer class. Both have shown great promise. Obviously, Tafamidis as a stabilizer is proven to be successful on the market. We believe that the silencer class is going to do very well. We believe the mechanism will be superior to other mechanisms and will be the preferred treatment of choice as first-line treatment, as well as for patients that progress on stabilizers. All patients eventually progress on stabilizers.